Prestige Consumer Healthcare Inc. (NYSE:PBH) Expected to Earn Q3 2026 Earnings of $1.20 Per Share

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Stock analysts at Zacks Research lifted their Q3 2026 earnings per share estimates for shares of Prestige Consumer Healthcare in a research note issued on Thursday, May 2nd. Zacks Research analyst R. Department now forecasts that the company will earn $1.20 per share for the quarter, up from their prior estimate of $1.19. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.33 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare’s FY2026 earnings at $4.76 EPS.

A number of other brokerages also recently issued reports on PBH. TheStreet raised Prestige Consumer Healthcare from a “c+” rating to a “b-” rating in a research report on Monday, February 12th. StockNews.com upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research report on Saturday, February 10th. One investment analyst has rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $110.00.

Prestige Consumer Healthcare Stock Up 0.0 %

Shares of PBH opened at $70.02 on Monday. The company has a current ratio of 3.09, a quick ratio of 1.92 and a debt-to-equity ratio of 0.75. Prestige Consumer Healthcare has a 12 month low of $55.96 and a 12 month high of $75.31. The firm’s 50 day moving average is $71.12 and its 200-day moving average is $64.73. The stock has a market capitalization of $3.48 billion, a PE ratio of -42.69, a P/E/G ratio of 1.90 and a beta of 0.53.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, February 8th. The company reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $1.04 by $0.02. The firm had revenue of $282.74 million for the quarter, compared to analyst estimates of $280.25 million. Prestige Consumer Healthcare had a positive return on equity of 14.09% and a negative net margin of 7.11%. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the prior year, the firm posted $1.04 EPS.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC bought a new position in Prestige Consumer Healthcare in the 4th quarter valued at approximately $25,000. Provence Wealth Management Group acquired a new stake in shares of Prestige Consumer Healthcare during the 3rd quarter valued at $26,000. Pacer Advisors Inc. grew its position in Prestige Consumer Healthcare by 85.7% during the 4th quarter. Pacer Advisors Inc. now owns 442 shares of the company’s stock worth $27,000 after acquiring an additional 204 shares during the last quarter. Principal Securities Inc. acquired a new position in Prestige Consumer Healthcare in the 4th quarter worth about $29,000. Finally, ORG Partners LLC bought a new position in Prestige Consumer Healthcare in the fourth quarter valued at about $36,000. Institutional investors own 99.95% of the company’s stock.

Insider Buying and Selling at Prestige Consumer Healthcare

In other news, SVP Mary Beth Fritz sold 5,336 shares of Prestige Consumer Healthcare stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $69.00, for a total value of $368,184.00. Following the transaction, the senior vice president now owns 15,934 shares in the company, valued at approximately $1,099,446. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 1.60% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.